Fresh Tracks Therapeutics, Inc. announced publication of data from preclinical studies of FRTX-02, a potential first-in-class, orally bioavailable DYRK1A inhibitor, in the Journal of Translational Autoimmunity. The paper shows FRTX-02 to be a potent and selective inhibitor of DYRK1A with the potential to restore immune homeostasis by regulating adaptive and innate immune system responses in models of various autoimmune and inflammatory diseases. Key preclinical findings as published in Journal of Translational Autoimmunity suggest the novel FRTX-02: Attenuates inflammation in mouse models of atopic dermatitis and psoriasis, implying potential as a treatment for various autoimmune and inflammatory diseases; Restores the adaptive immune system through promotion of Treg differentiation and suppression of pro-inflammatory Th17 and Th1 differentiation; Induces alternative splicing of myeloid differentiation primary response 88 (MyD88), thereby regulating the innate immune system by blocking Interleukin-1 receptor-associated kinase 4 (IRAK4) phosphorylation; and Has the potential to restore immune homeostasis, presenting a novel approach to regulating adaptive and innate inflammatory immune responses.